United Asset Strategies Inc. Trims Holdings in Thermo Fisher Scientific Inc. $TMO

United Asset Strategies Inc. trimmed its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 27.9% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 26,211 shares of the medical research company’s stock after selling 10,128 shares during the period. United Asset Strategies Inc.’s holdings in Thermo Fisher Scientific were worth $10,627,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealth Alliance LLC raised its stake in shares of Thermo Fisher Scientific by 40.6% during the second quarter. Wealth Alliance LLC now owns 2,841 shares of the medical research company’s stock worth $1,152,000 after purchasing an additional 821 shares during the last quarter. Quinn Opportunity Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $1,216,000. M&G PLC increased its stake in shares of Thermo Fisher Scientific by 233.1% during the second quarter. M&G PLC now owns 393,766 shares of the medical research company’s stock worth $159,475,000 after acquiring an additional 275,547 shares during the period. Fairbanks Capital Management Inc. lifted its position in Thermo Fisher Scientific by 6.7% in the second quarter. Fairbanks Capital Management Inc. now owns 1,827 shares of the medical research company’s stock valued at $741,000 after purchasing an additional 115 shares during the period. Finally, VeraBank N.A. increased its position in Thermo Fisher Scientific by 39.0% during the 2nd quarter. VeraBank N.A. now owns 1,617 shares of the medical research company’s stock worth $656,000 after purchasing an additional 454 shares during the period. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $586.37 on Wednesday. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97. The company has a market capitalization of $220.30 billion, a price-to-earnings ratio of 33.87, a PEG ratio of 3.27 and a beta of 0.82. The company’s 50 day simple moving average is $522.26 and its 200 day simple moving average is $465.01. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.11 and a current ratio of 1.50.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. The business had revenue of $11.12 billion during the quarter, compared to the consensus estimate of $10.90 billion. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business’s revenue for the quarter was up 4.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.28 earnings per share. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific announced that its Board of Directors has authorized a stock buyback program on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to buy up to 2.4% of its shares through open market purchases. Shares repurchase programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 9.94%.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the transaction, the chief accounting officer owned 2,319 shares in the company, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Lisa P. Britt sold 10,225 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president directly owned 14,145 shares of the company’s stock, valued at $8,085,564.90. The trade was a 41.96% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 46,645 shares of company stock valued at $25,825,699. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have issued reports on TMO. Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, October 8th. Argus boosted their price objective on shares of Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Evercore ISI lifted their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Leerink Partners lifted their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Finally, Barclays raised their price target on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a research report on Thursday, October 23rd. Nineteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $601.65.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.